Implementation of pan-enteric PCR screening at a UK general district hospital – benefits, pitfalls and lessons learnt
Implementation of pan-enteric PCR screening at a UK general district hospital – benefits, pitfalls and lessons learnt Presented by Elisabetta Savanco Senior Biomedical Scientist in Medical Microbiology at Blackpool Teaching Hospitals NHS Foundation Trust Gastroenteritis is a significant socioeconomic burden. It is crucial to identify or exclude infectious causes of gastroenteritis, as this informs treatment…
Read MoreMolecular Testing for Intestinal Protozoa: How a Laboratory Developed Test Compares to One That Is FDA-Cleared
Molecular Testing for Intestinal Protozoa: How a Laboratory Developed Test Compares to One That Is FDA-Cleared Presented by Dr Susan Madison-Antenucci Lab Chief of Bloodborne and Parasitic Diseases, New York State Department of Health, Wadsworth Center Assistant Professor – Biomedical Sciences. Assistant Professor – Environmental Health Sciences, College of Integrated Health Sciences, University at Albany.…
Read MoreInvestor Presentation – Finance Network
Genetic Signatures’ CEO, John Melki, talks with Nadine Blayney from AusBiz
Genetic Signatures’ CEO Dr John Melki was recently interviewed by Nadine Blayney from AusBiz about the Company’s unique 3base® technology, its advantages for detecting infectious diseases, the development pipeline, revenue sources, and plans for further investment and expansion in key international markets.
Read MoreSydPath Supports NSW COVID-19 Outbreak with Genetic Signatures’ Testing Technology
Channel 9 interviews our customer SydPath, taking a look at their increased testing capabilities in response to the COVID-19 outbreak in NSW, implementing our high-throughput testing technology for respiratory infection
Read MoreJohn Melki speaking at ASX Small and Mid-Cap Conference
Genetic Signatures’ CEO- Dr. John Melki speaking at ASX Small and Mid-Cap Conference held in Sydney Australia September 2018
Read More